BamSEC and AlphaSense Join Forces
Learn More

Erasca Inc. – Material Contracts

NASDAQ: ERAS    
Share price (5/22/26): $11.24    
Market cap (5/22/26): $3.495 billion
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.1
from 10-Q 5 pages Erasca, Inc. Non-Employee Director Compensation Program Updated December 17, 2024
12/34/56
EX-10.2
from 10-Q 51 pages Certain Confidential Information Contained in This Document, Marked by [***], Has Been Omitted Because It Is Both (1) Not Material and (2) Would Be Competitively Harmful if Publicly Disclosed License Agreement
12/34/56
EX-10.1
from 10-Q 77 pages Certain Confidential Information Contained in This Document, Marked by [***], Has Been Omitted Because It Is Both (1) Not Material and (2) Would Be Competitively Harmful if Publicly Disclosed License Agreement
12/34/56
EX-10.1
from 8-K 40 pages Erasca, Inc. Stock Purchase Agreement
12/34/56
EX-10.18
from 10-K 5 pages Erasca, Inc. Non-Employee Director Compensation Program Updated December 12, 2023
12/34/56
EX-10.1
from 10-Q 4 pages Background
12/34/56
EX-10.1
from 10-Q 6 pages This Amended and Restated Employment Letter Agreement (This “Agreement”) Amends and Restates That Certain Employment Offer Letter, Dated as of May 2, 2022 (The “Prior Agreement”), by and Between You and Erasca, Inc. (The “Company”). This Agreement Will Serve to Memorialize the Terms of Your Continued Employment With the Company as Provided in This Agreement, Effective as of April 10, 2022
12/34/56
EX-10
from 10-K 59 pages Exclusive License Agreement
12/34/56
EX-10.2
from 10-Q 68 pages Lease Agreement
12/34/56
EX-10.1
from 10-Q 102 pages Lease by and Between Bmr-Road to the Cure LP, a Delaware Limited Partnership and Erasca, Inc., a Delaware Corporation
12/34/56
EX-10.16
from 10-K 89 pages Exclusive License Agreement by and Between Katmai Pharmaceuticals, Inc. and Erasca, Inc. Dated as of March 12, 2020
12/34/56
EX-10.13
from 10-K 97 pages Lease by and Between Bmr-Road to the Cure LP, a Delaware Limited Partnership and Erasca, Inc., a Delaware Corporation
12/34/56
EX-10.17
from S-1/A 17 pages Indemnification Agreement
12/34/56
EX-10.16
from S-1/A 5 pages July 9, 2021 Ebun Garner Re: Amended and Restated Employment Letter Agreement Dear Ebun: O Base Salary. the Semi-Monthly Pay for This Position Is $16,425, Equivalent to an Annual Base Salary of $394,200 Less Applicable Taxes and Other Withholdings According to the Company’s Normal Payroll Practices. O Annual Bonus. You Are Also Eligible for a Bonus of Up to 40% of Your Base Salary, Prorated for Days Worked Based on Your Hire Date, Subject to the Approval by the Board of Directors and Achievement of Corporate and Individual Performance Goals
12/34/56
EX-10.15
from S-1/A 6 pages July 9, 2021 Wei Lin, M.D. Re: Amended and Restated Employment Letter Agreement Dear Wei
12/34/56
EX-10.14
from S-1/A 5 pages July 9, 2021 David Chacko, M.D. Re: Amended and Restated Employment Letter Agreement Dear David: O Base Salary. You Will Receive an Annual Base Salary of $406,900 for All Hours Worked, to Be Paid in Accordance With the Company’s Customary Payroll Procedures
12/34/56
EX-10.13
from S-1/A 5 pages July 9, 2021 Jonathan Lim, M.D. Re: Amended and Restated Employment Letter Agreement Dear Jonathan: O Base Salary. You Will Receive an Annual Base Salary of $549,900 for All Hours Worked, to Be Paid in Accordance With the Company’s Customary Payroll Procedures
12/34/56
EX-10.5
from S-1/A 3 pages Erasca, Inc. Non-Employee Director Compensation Program
12/34/56
EX-10.4
from S-1/A 41 pages Erasca, Inc. Severance and Change in Control Severance Plan and Summary Plan Description
12/34/56
EX-10.3
from S-1/A 15 pages Erasca, Inc. 2021 Employee Stock Purchase Plan
12/34/56